Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cance

Supplemental Table 3 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental table 3. Nanostring nCounter Differential gene expression (excel file) -uploading separately.</p

Supplementary Figure 3 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Figure 3. Validation of RNA seq results of responders by Nanostring nCounter gene expression assay</p

Supplemental Table 2 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental table 2. Differential gene expression and pathway enrichment analysis in placebo responders (excel file) -uploading separately.</p

Supplementary Table 1 from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer

Supplementary Table 1: All Adverse Events related to topical 1% bexarotene gel.</p

Supplementary Figure 4 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Figure 4. Plots showing changes in serum estradiol (left panel) and serum progesterone (right panel) in three subgroups: placebo, TPA-treated Ki67 responders and TPA-treated Ki67-nonresponders.</p

Supplemental Table 1 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental table 1. Differential gene expression and pathway enrichment analysis in TPA responders (excel file) -uploading separately.</p

Supplementary Figure 1 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Figure 1. Validation of RNA seq results of responders by Nanostring nCounter gene expression assay.</p

Supplemental Materials from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Materials Supplemental Table 4. Changes in serum sex hormone concentrations according to the treatments. Supplemental Table 5. Summary of BESS Quality of Life Assessment by symptom clusters according to the treatments Supplemental Table 6. Summary of Adverse Effects.</p

Supplementary Figure 2 from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate

Supplemental Figure 2. Ki67 Change relative to treatment duration. There was no significant correlation between change in Ki67 and treatment duration, in either TPA or placebo arms.</p